Erman Akkus, Medical Oncology Fellow at Ankara University, shared a post X:
“KRAS mutations and biliary tract cancers JCO Precision Oncology.
- Mutation frequency: 15%
- KRAS G12D was the most common
- KRAS G12 mutations worse OS in intrahepatic CCA
- KRAS-targeted treatments.
Title: KRAS Variants Are Associated With Survival Outcomes and Genomic Alterations in Biliary Tract Cancers
Authors: Rebecca Gelfer, Aiste Gulla, Hannah L. Kalvin, Yi Song, James Harding, Ghassan K. Abou-Alfa, Eileen M. O’Reilly, Wungki Park, Rohit Chandwani, Alice Wei, Peter Kingham, Jeffrey Drebin, Vinod Balachandran, Michael D’Angelica, Kevin Soares, Mithat Gonen and William R. Jarnagin
Erman Akkus is a medical oncology fellow at the Ankara University, Faculty of Medicine. Previously, he was an Internal Medicine Resident at the Ankara University, Faculty of Medicine. He was also a Visiting Researcher at the University of Oslo. He completed his education from the Medical University of Vienna.
More posts featuring Erman Akkus.
